Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Geographic, Racial, and Sex Disparities in Time to Treatment for Early-Onset Colorectal Cancer.

JAMA network open·2026
Same author

Antireflux Surgery for Barrett's Esophagus: Where Do We Stand in Preventing Esophageal Adenocarcinoma?

Annals of the New York Academy of Sciences·2026
Same author

Unicentric Hyaline-Vascular Castleman Disease Presenting as a Periduodenal Mass: A Rare Retroperitoneal Manifestation.

Cureus·2025
Same author

Age-related disparities in survival following colorectal cancer diagnosis in an underserved community in Georgia: A retrospective cohort analysis.

Journal of geriatric oncology·2025
Same author

Racial/Ethnic and Age-Related Disparities in Early-Onset Colorectal Cancer Diagnoses and Survival.

Cancer control : journal of the Moffitt Cancer Center·2025
Same author

Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis.

The American journal of gastroenterology·2025
Same journal

Comment on 'Associations between 12 insulin resistance surrogates with metabolic dysfunction-associated steatotic liver disease risk and all-cause mortality: data from the National Health and Nutrition Examination Survey III (1988-1994)'.

European journal of gastroenterology & hepatology·2026
Same journal

Alarm symptoms at diagnosis of coeliac disease and long-term outcomes.

European journal of gastroenterology & hepatology·2026
Same journal

Artificial intelligence-integrated nanotherapeutics for rare Peutz-Jeghers syndrome hamartoma-induced obstructions: latest clearance strategies.

European journal of gastroenterology & hepatology·2026
Same journal

'Presence of alarm symptoms at coeliac disease diagnosis is not associated with poorer long-term treatment outcomes' [Letter].

European journal of gastroenterology & hepatology·2026
Same journal

Atrial fibrillation in patients with alcohol-associated hepatitis leads to increased mortality.

European journal of gastroenterology & hepatology·2026
Same journal

Association between albumin-bilirubin score, model for end-stage liver disease score, platelet-albumin-bilirubin score, and acute-on-chronic liver failure complications: a cross-sectional study in a Chinese population.

European journal of gastroenterology & hepatology·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Sandostatin causing reversible thrombocytopenia.

Sian Chisholm1, Bharat Gummadi, Kenneth J Vega

  • 1Division of General Internal Medicine, University of Florida Health Sciences Center, Jacksonville, Florida 32207, USA.

European Journal of Gastroenterology & Hepatology
|February 27, 2009
PubMed
Summary
This summary is machine-generated.

Sandostatin can cause a dangerous drop in platelet count (thrombocytopenia), especially during esophageal variceal bleeding. This condition is reversible by stopping the drug, highlighting the need for physician awareness.

More Related Videos

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography
06:44

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

Published on: April 13, 2018

Related Experiment Videos

Last Updated: Jun 25, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography
06:44

Deep Vein Thrombosis Induced by Stasis in Mice Monitored by High Frequency Ultrasonography

Published on: April 13, 2018

Area of Science:

  • Gastroenterology
  • Hematology
  • Pharmacology

Background:

  • Esophageal variceal bleeding is a severe condition.
  • Drug-induced thrombocytopenia can worsen bleeding episodes.
  • Sandostatin is a medication used in managing variceal bleeding.

Observation:

  • A rare case of Sandostatin-induced thrombocytopenia was observed.
  • Thrombocytopenia developed during Sandostatin administration.
  • Platelet counts recovered upon drug discontinuation.

Findings:

  • The study presents a case of reversible thrombocytopenia linked to Sandostatin.
  • A positive rechallenge confirmed the drug's role.
  • An immunologic mechanism is proposed for the thrombocytopenia.

Implications:

  • Physician awareness of this side effect is crucial.
  • Early recognition and drug cessation can prevent complications.
  • This finding aids in managing patients with esophageal variceal bleeding.